Theremia

Executive Summary

Theremia is a French AI/ML biotech company founded in 2021, headquartered in Paris, developing a precision medicine platform to optimize drug development and treatment outcomes in neurology and psychiatry. By analyzing massive health datasets, the platform aims to predict and prevent adverse drug reactions, enabling personalized therapy selection for patients with neurological and psychiatric disorders. As a private, early-stage company, Thermia has not disclosed funding rounds or valuation, but its focus on AI-driven drug safety and efficacy positions it within a growing trend of digital therapeutics and precision psychiatry. The company's proprietary algorithms and data integration capabilities could reduce clinical trial failures and improve real-world patient outcomes, though it faces competition from established players and regulatory hurdles. With no disclosed products or partnerships, Thermia remains pre-revenue and likely in the R&D phase. The limited public information and low profile suggest high risk, but the potential for transformative impact in neurology and psychiatry justifies continued monitoring. Conviction score: 35/100 due to lack of clinical data, funding transparency, and commercial traction.

Upcoming Catalysts (preview)

• Q4 2026Series A funding announcement60% success
• Q1 2027Pharmaceutical partnership for platform validation40% success
• Q2 2027Publication of proof-of-concept data in neurology50% success